Trial Information

Summary: ALTITUDE Diabetes Study CSPP100E2337

Novartis is conducting this clinical research study is to determine if the investigational drug aliskiren delays or prevents the occurrence of heart and/or kidney complications in participants with type 2 diabetes who are taking medications for heart and/or kidney problems. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Depending on when participants join this study, their participation may last for two to four years with up to 23 scheduled visits.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 2, 2008 at 1:59:05 PM